Switch theme
Sign up to access all valuation multiples
Arrowhead Pharmaceuticals Inc is an American biotechnology company. Its main target is the development of medicine to treat diseases with a genetic origin, characterized by the overproduction of one or more proteins. Its medical solutions are aimed at the genes that trigger the diseases. Its portfolio includes drugs targeting cardiovascular, Cardiometabolic, Central Nervous System, Pulmonary, Liver, Muscular, and Complement Mediated Disease. It majority products are liver disease curable.
1989
609
LTM Revenue $184M
LTM EBITDA -$478M
$1.7B
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Arrowhead Pharmaceuticals has a last 12-month revenue of $184M and a last 12-month EBITDA of -$478M.
In the most recent fiscal year, Arrowhead Pharmaceuticals achieved revenue of $3.6M and an EBITDA of -$562M.
Arrowhead Pharmaceuticals expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Arrowhead Pharmaceuticals valuation multiples based on analyst estimates| FY 2023 | FY 2024 | FY 2025 | LTM | NTM | |
|---|---|---|---|---|---|
| Revenue | $241M | $3.6M | XXX | XXX | XXX |
| Gross Profit | n/a | n/a | XXX | XXX | XXX |
| Gross Margin | NaN% | NaN% | XXX | XXX | XXX |
| EBITDA | -$176M | -$562M | XXX | XXX | XXX |
| EBITDA Margin | -73% | -15813% | XXX | XXX | XXX |
| Net Profit | -$176M | -$205M | XXX | XXX | XXX |
| Net Margin | -73% | -5781% | XXX | XXX | XXX |
| Net Debt | n/a | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of April 15, 2025, Arrowhead Pharmaceuticals's stock price is $12.
Arrowhead Pharmaceuticals has current market cap of $1.7B, and EV of $1.7B.
See Arrowhead Pharmaceuticals trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $1.7B | $1.7B | XXX | XXX | XXX | XXX | $-3.73 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Sign UpAs of April 15, 2025, Arrowhead Pharmaceuticals has market cap of $1.7B and EV of $1.7B.
Arrowhead Pharmaceuticals's trades at 9.1x LTM EV/Revenue multiple, and -3.5x LTM EBITDA.
Analysts estimate Arrowhead Pharmaceuticals's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See valuation multiples for Arrowhead Pharmaceuticals and 10K+ public comps| FY 2024 | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|
| EV | $1.7B | XXX | XXX | XXX |
| EV/Revenue | 19.1x | XXX | XXX | XXX |
| EV/EBITDA | -3.2x | XXX | XXX | XXX |
| P/E | -3.1x | XXX | XXX | XXX |
| P/E/Growth | n/a | XXX | XXX | XXX |
| EV/FCF | -4.3x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Sign UpArrowhead Pharmaceuticals's NTM/LTM revenue growth is 50%
Arrowhead Pharmaceuticals's revenue per employee for the last fiscal year averaged $6K, while opex per employee averaged $1.0M for the same period.
Over next 12 months, Arrowhead Pharmaceuticals's ratio of sales and marketing spend to revenue is estimated to be XXX , while its R&D spend to revenue to be XXX .
Analysts estimate Arrowhead Pharmaceuticals's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See operational valuation multiples for Arrowhead Pharmaceuticals and other 10K+ public comps| FY 2024 | NTM | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|---|
| Revenue Growth | -99% | XXX | XXX | XXX | XXX |
| EBITDA Margin | -593% | XXX | XXX | XXX | XXX |
| EBITDA Growth | 220% | XXX | XXX | XXX | XXX |
| Rule of 40 (SaaS-only) | -543% | XXX | XXX | XXX | XXX |
| Revenue per Employee | $6K | XXX | XXX | XXX | XXX |
| Opex per Employee | $1.0M | XXX | XXX | XXX | XXX |
| S&M Expenses to Revenue | n/a | XXX | XXX | XXX | XXX |
| G&A Expenses to Revenue | 2727% | XXX | XXX | XXX | XXX |
| R&D Expenses to Revenue | 14246% | XXX | XXX | XXX | XXX |
| Opex to Revenue | 17027% | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Benevolent AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Arrowhead Pharmaceuticals acquired XXX companies to date.
Last acquisition by Arrowhead Pharmaceuticals was XXXXXXXX, XXXXX XXXXX XXXXXX . Arrowhead Pharmaceuticals acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Sign Up| When was Arrowhead Pharmaceuticals founded? | Arrowhead Pharmaceuticals was founded in 1989. |
| Where is Arrowhead Pharmaceuticals headquartered? | Arrowhead Pharmaceuticals is headquartered in United States of America. |
| How many employees does Arrowhead Pharmaceuticals have? | As of today, Arrowhead Pharmaceuticals has 609 employees. |
| Who is the CEO of Arrowhead Pharmaceuticals? | Arrowhead Pharmaceuticals's CEO is Dr. Christopher Anzalone,PhD. |
| Is Arrowhead Pharmaceuticals publicy listed? | Yes, Arrowhead Pharmaceuticals is a public company listed on NAS. |
| What is the stock symbol of Arrowhead Pharmaceuticals? | Arrowhead Pharmaceuticals trades under ARWR ticker. |
| When did Arrowhead Pharmaceuticals go public? | Arrowhead Pharmaceuticals went public in 1997. |
| Who are competitors of Arrowhead Pharmaceuticals? | Similar companies to Arrowhead Pharmaceuticals include e.g. Julphar, Benevolent AI, Galapagos, Pharming. |
| What is the current market cap of Arrowhead Pharmaceuticals? | Arrowhead Pharmaceuticals's current market cap is $1.7B |
| What is the current revenue of Arrowhead Pharmaceuticals? | Arrowhead Pharmaceuticals's last 12-month revenue is $184M. |
| What is the current EBITDA of Arrowhead Pharmaceuticals? | Arrowhead Pharmaceuticals's last 12-month EBITDA is -$478M. |
| What is the current EV/Revenue multiple of Arrowhead Pharmaceuticals? | Current revenue multiple of Arrowhead Pharmaceuticals is 9.1x. |
| What is the current EV/EBITDA multiple of Arrowhead Pharmaceuticals? | Current EBITDA multiple of Arrowhead Pharmaceuticals is -3.5x. |
| What is the current revenue growth of Arrowhead Pharmaceuticals? | Arrowhead Pharmaceuticals revenue growth between 2023 and 2024 was -99%. |
| Is Arrowhead Pharmaceuticals profitable? | Yes, Arrowhead Pharmaceuticals is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
